The organ preservation solution market size is projected to reach US$ 512.62 million by 2031 from US$ 274.41 million in 2023. The market is expected to register a CAGR of 8.2% during 2023–2031. The shift toward machine perfusion technique is likely to remain a key trend in the market.
Organ preservation solution is a specialized fluid used to preserve organs such as kidney, heart, liver, and pancreas outside the body during transplantation. Organ transplantation is the only treatment option for patients with end-stage organ failure. The increasing prevalence of chronic diseases and the rising need for organ transplantation are the factors favoring the organ preservation solution market progress.
In 2023, the Canadian Institute for Health Information (CIHI) reported that 3,428 organ transplant procedures were performed in the country. Of these transplants, 83% used organs from deceased donors, and 17% used organs from living donors. Thus, the growing number of organ transplant procedures serves growth prospects for the organ preservation solution market. Governments of various countries are collaborating with the market players to understand perfusion systems for better health. For instance, China has installed XVIVO perfusion in its hospitals, and the company is also seeking approval from CFDA.
Chronic kidney disease (CKD) is a common and potentially fatal condition that affects approximately 1 in every 10 people worldwide. A study published by the National Kidney Foundation in 2020 predicted that ~35.0% of the diabetic population over the age of 20 would develop chronic kidney disease over time. As per the Health Resources and Services Administration (HRSA), ~88,901 patients were on the kidney waiting list as of 2022. Each day, nearly 21 individuals die while waiting for organ transplantation, whereas over 120,000 men, women, and children seek life-saving organ transplantation procedures. Chronic diseases, which may be congenital or acquired, can lead to gradual damage to organs over time. Chronic diseases typically don't resolve on their own, but there may be ways to slow down or mitigate the damage caused by the condition. It may take decades for this damage to build up to the point where it noticeably affects patients' organ function or requires medical intervention. Chronic heart diseases, including coronary artery disease and congenital heart disease, can lead to progressive heart failure. Thus, the mounting prevalence of chronic diseases increases the demand for organ preservation solutions during organ transplantation procedures.
Various market players focus on product launches or strategic collaborations to develop advanced products that help ease the treatment of chronic disorders. There have been various recent developments, such as product launches, mergers, and acquisitions in recent years.
Thus, a surge in product approvals, launches, and strategic collaborations is likely to create considerable growth opportunities for the organ preservation solution market in the future.
Key segments that contributed to the derivation of the organ preservation solution market analysis are product, type, application, and end user.
The geographic scope of the organ preservation solution market report is mainly divided into five regions: North America, Asia Pacific, Europe, the Middle East & Africa, and South & Central America. North America dominated the market in 2023. The North America organ preservation solution market has been analyzed on the basis of the US, Canada, and Mexico. Increasing adoption of technologically advanced products and solutions, and surging number of organ transplants are the factors benefiting the organ preservation solution market in this region. The US held the largest share of the organ preservation solution market in North America in 2023. In June 2024, the American Kidney Fund, Inc. reported that up to 37 million Americans have kidney disease, and ~808,000 Americans are affected by kidney failure. More than 557,000 Americans are undergoing dialysis treatment. The prevalence of kidney disease is rising and currently affects over 1 in 7 (or 14%) of American adults.
The rising number of approvals from the US Food and Drug Administration (FDA), and the presence of market players further boost the organ preservation solution market growth in the US. In April 2022, TransMedics Group, Inc. announced that it received premarket FDA approval for its OCS Heart System, which can be used with organs from donors after circulatory death (DCD). The OCS Heart System is approved with the extended clinical indication for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death (DCD) hearts.
The regional trends and factors influencing the Organ Preservation Solution Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Organ Preservation Solution Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 274.41 Million |
| Market Size by 2031 | US$ 512.62 Million |
| Global CAGR (2023 - 2031) | 8.2% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Organ Preservation Solution Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Organ Preservation Solution Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The organ preservation solution market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the organ preservation solution market are listed below:
The "Organ Preservation Solution Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
The List of Companies - Organ Preservation Solution Market
The organ preservation solutions market majorly consists of the players, including Waters Medical Systems LLC, XVIVO Perfusion, TransMedics, OrganOx Limited, Paragonix Technologies, Inc, Dr. Franz Koehler Chemie GmbH, Accord Healthcare, ST CENTURY MEDICINE, Shanghai Genext Pharmaceutical Technology, and Bridge to Life Ltd.
The organ preservation solutions market was valued at US$ 274.41 million in 2023.
The organ preservation solutions market is expected to be valued at US$ 512.62 million by 2031.
The organ preservation solutions market, by product, is segmented into University of Wisconsin Solution, Custodiol HTK, Perfadex, Hypothermosol, and Others. The University of Wisconsin Solution segment held the largest organ preservation solution market share in 2023.
The factors driving the growth of the organ preservation solutions market include the increasing prevalence of chronic diseases and the rising need for organ transplantation. However, the expensive organ transplant surgeries and limited organ availability hampers the growth of the Organ preservation solutions market.
Organ preservation solution is a specialized fluid used to preserve organs such as kidney, heart, liver, and pancreas outside the body during transplantation. Organ transplantation is the only treatment option for patients with end-stage organ failure.